COLL
Price
$34.62
Change
+$0.28 (+0.82%)
Updated
Jun 12, 04:59 PM (EDT)
Capitalization
1.12B
48 days until earnings call
Intraday BUY SELL Signals
EOLS
Price
$6.74
Change
+$0.23 (+3.53%)
Updated
Jun 12, 04:59 PM (EDT)
Capitalization
443.2M
54 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

COLL vs EOLS

Header iconCOLL vs EOLS Comparison
Open Charts COLL vs EOLSBanner chart's image
COLL vs EOLS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
COLL vs. EOLS commentary
Jun 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a Buy and EOLS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 13, 2026
Stock price -- (COLL: $34.64 vs. EOLS: $6.73)
Brand notoriety: COLL and EOLS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: COLL: 61% vs. EOLS: 76%
Market capitalization -- COLL: $1.12B vs. EOLS: $443.2M
COLL [@Pharmaceuticals: Generic] is valued at $1.12B. EOLS’s [@Pharmaceuticals: Generic] market capitalization is $443.2M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COLL’s FA Score shows that 0 FA rating(s) are green whileEOLS’s FA Score has 0 green FA rating(s).

  • COLL’s FA Score: 0 green, 5 red.
  • EOLS’s FA Score: 0 green, 5 red.
According to our system of comparison, COLL is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COLL’s TA Score shows that 6 TA indicator(s) are bullish while EOLS’s TA Score has 4 bullish TA indicator(s).

  • COLL’s TA Score: 6 bullish, 4 bearish.
  • EOLS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, COLL is a better buy in the short-term than EOLS.

Price Growth

COLL (@Pharmaceuticals: Generic) experienced а +3.77% price change this week, while EOLS (@Pharmaceuticals: Generic) price change was +0.90% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.56%. For the same industry, the average monthly price growth was +23.25%, and the average quarterly price growth was +9.77%.

Reported Earning Dates

COLL is expected to report earnings on Jul 30, 2026.

EOLS is expected to report earnings on Aug 05, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.56% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COLL($1.12B) has a higher market cap than EOLS($443M). EOLS YTD gains are higher at: 1.203 vs. COLL (-25.184). COLL has higher annual earnings (EBITDA): 411M vs. EOLS (-13.7M). COLL has more cash in the bank: 422M vs. EOLS (49.8M). EOLS has less debt than COLL: EOLS (165M) vs COLL (808M). COLL has higher revenues than EOLS: COLL (796M) vs EOLS (302M).
COLLEOLSCOLL / EOLS
Capitalization1.12B443M254%
EBITDA411M-13.7M-3,000%
Gain YTD-25.1841.203-2,093%
P/E Ratio16.82N/A-
Revenue796M302M264%
Total Cash422M49.8M847%
Total Debt808M165M490%
FUNDAMENTALS RATINGS
COLL vs EOLS: Fundamental Ratings
COLL
EOLS
OUTLOOK RATING
1..100
425
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
71
Overvalued
PROFIT vs RISK RATING
1..100
65100
SMR RATING
1..100
35100
PRICE GROWTH RATING
1..100
5947
P/E GROWTH RATING
1..100
82100
SEASONALITY SCORE
1..100
2850

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COLL's Valuation (53) in the Pharmaceuticals Other industry is in the same range as EOLS (71) in the Pharmaceuticals Major industry. This means that COLL’s stock grew similarly to EOLS’s over the last 12 months.

COLL's Profit vs Risk Rating (65) in the Pharmaceuticals Other industry is somewhat better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that COLL’s stock grew somewhat faster than EOLS’s over the last 12 months.

COLL's SMR Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that COLL’s stock grew somewhat faster than EOLS’s over the last 12 months.

EOLS's Price Growth Rating (47) in the Pharmaceuticals Major industry is in the same range as COLL (59) in the Pharmaceuticals Other industry. This means that EOLS’s stock grew similarly to COLL’s over the last 12 months.

COLL's P/E Growth Rating (82) in the Pharmaceuticals Other industry is in the same range as EOLS (100) in the Pharmaceuticals Major industry. This means that COLL’s stock grew similarly to EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COLLEOLS
RSI
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
72%
Momentum
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 11 days ago
65%
Bearish Trend 10 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
COLL
Daily Signal:
Gain/Loss:
EOLS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ALVAX23.830.24
+1.02%
American Beacon Large Cap Value A
RIGIX49.870.24
+0.48%
American Funds Intl Gr and Inc R5E
GEGAX21.15N/A
N/A
abrdn Emerging Markets A
HGXAX18.89N/A
N/A
Hartford Global Impact A
HMSFX12.91N/A
N/A
Hennessy Midstream Investor

COLL and

Correlation & Price change

A.I.dvisor indicates that over the last year, COLL has been loosely correlated with AMPH. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then AMPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
+0.87%
AMPH - COLL
42%
Loosely correlated
-2.12%
AMRX - COLL
42%
Loosely correlated
-0.86%
VTRS - COLL
38%
Loosely correlated
+0.98%
EBS - COLL
37%
Loosely correlated
-0.83%
ANIP - COLL
34%
Loosely correlated
-0.01%
More

EOLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EOLS has been loosely correlated with LNTH. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if EOLS jumps, then LNTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EOLS
1D Price
Change %
EOLS100%
+3.38%
LNTH - EOLS
35%
Loosely correlated
+0.19%
PRGO - EOLS
27%
Poorly correlated
+0.83%
COLL - EOLS
26%
Poorly correlated
+0.87%
ACET - EOLS
26%
Poorly correlated
+6.62%
INM - EOLS
26%
Poorly correlated
-3.80%
More